Endocrine Pharm Flashcards
Biguanides - Metformin
MOA
ADE
MOA:
inhibit hepatic gluconeogenesis & glucagon (inhibit mGPD)
Increase glycolysis & insulin sensitivity (glucose uptake)
Lactic Acidosis
GI upset, weight loss
B12 def
Sulfonylureas 1st gen - chlorpropamide, tolbutamide 2nd gen - glipizide, glyburide, glimepiride MOA ADE
MOA:
close K channel in pancreatic beta cell
=> depol => Ca in => insulin secreted
hypoglycemia, weight gain
1st gen - disulfiram rxn
Meglitinides
nateglitide
repaglitide
MOA
ADE
MOA:
close K channel in pancreatic beta cell
=> depol => Ca in => insulin secreated
hypoglycemia, weight gain
Thiazolidinediones
pioglitazone, rosiglitazone
MOA
bind intranuclear PPAR-y TF
=> increased insulin sensitivity & adiponectin
=> regulation of glucose met & FA storage
Weight gain, edema, HF, increased risk fractures
DPP-4 Inhibitors
Linagliptin, saxagliptin, sitagliptin
Inhibit DPP-4 (DPP-4–| GLP-1) => increased GLP-1
=> increased glucose dependent insulin release, decreased glucagon release, gastric emptying (satiety)
mild URI/UTI, weight neutral
GLP-1 Analogues - Injected
Liraglutide, Exenatide
MOA
ADE
MOA:
increased glucose dependent insulin release,
decreased glucagon release, gastric emptying (satiety)
N/V, pancreatitis, promotes weight loss
SGLT2 inhibitors
canagliflozin, dapagliflozin, empagliflozin
MOA
ADE
MOA: block Glucose (and Na) resorption in PCT
Glucosuria, dehydration, UTI, vaginal yeast infxn
hyperK, weight loss
alpha-glucosidase inhibitors
acarbose, miglotol
MOA
ADE
MOA:
inhibit intestinal brush border alpha-glucosidase
=> delayed carb hydrolysis and glucose absorption
GI upset
Thioamides
MOA
ADE
methimazole, propylthiouracil
MOA:
inhibit thyroid perioxidase
PTU blocks 5’-deiodinase => block peripheral conversion T4–>T3
agranulocytosis, aplastic anemia, hepatotoxicity, skin rash
Levothyroxine, Liothyronine
T4/T3 analogue
can be abused for weight loss (sx of hyperthyroid)